琚珏刚先生，目前在英矽智能担任临床运营负责人，管理所有临床研究项目从策略到运营交付的各种事宜，并涵盖人员/预算/流程等各方面的管理。同时也是CBA-GP中国区联络人。在加入英矽智能之前，琚珏刚先生曾在原力生命担任全球临床运营负责人，在岸阔医药担任产品开发策略和临床开发负责人，以及在昆拓/艾昆玮担任临床战略规划负责人。在此之前，琚珏刚先生曾在阿斯利康、安进/昆泰、诺华/昆泰和法码康担任过多项职务，涉及从全球临床研究的管理到研究中心的运营管理工作。琚珏刚先生毕业于上海交通大学，拥有科学学士和硕士学位。
Johnny Ju, currently as the Head of clinical operations in Insilico, responsible for clinical study projects from strategy to operational delivery, also covering the management of people / budget / process / etc. Also he is the point of contact in China for CBA-GP. Before joining in Insilico, Johnny had been the Global Clinical Operations Head in Ionova, Head of Product Development Strategy and Clinical Development in OnQuality, and Head of Clinical Strategy Planning in KunTuo/Quintiles. Even before, Johnny had taken multiple roles from Global clinical study management to site level operational management in AstraZeneca, Amgen/Quintiles, Novartis/Quintiles and Pharmacons. Johnny was graduated from Shanghai Jiao Tong University, with Bachelor and Master Degrees of Science.
王晓梅，北京大学医学部流行病与卫生统计学硕士。拥有10年以上国际项目管理经验和10年+Biotech公司创新药研发工作经验。熟悉药物研发临床前研究、IND申报和临床开发等工作，包括临床开发计划、临床试验方案制定；数据管理、统计分析、药物安全管理等领域，领导完成了多个在中国、美国和澳大利亚开展的I/II期临床试验，参与多个化合物中、美、澳新药临床试验IND申请和pre-IND沟通交流工作以及临床前研究工作。现负责凯复医药全球临床运营和法规注册工作。
Mrs. Wang received her Master of Epidemiology and Health Statistics from Peking University Health Science Center. With over 10 years of Global project management experience in China CDC and Damien Foundation Belgium and more than 10 years of innovative drug research and development experience in Biotech companies. She has been involved in preclinical research and development, IND application, and clinical operations, including data management, statistical analysis, and drug safety management. Mrs. Wang has led the completion of multiple Phase I and Phase II clinical trials in China, Australia, and the United States, and participated in the IND applications and pre– IND preparations, as well as preclinical researches for a variety of new drugs in China, Australia, and the United States. Currently she is in charge of the global clinical operations and regulatory affairs of Keythera Bio-Pharmaceuticals.
Shelly毕业于沈阳化工大学高分子化学专业，拥有超过15年在跨国制药企业（MNC）从事商业及临床供应链管理的经验。曾任职于科文斯、赛诺菲和安进等跨国药企，期间支持亚太研发中心的建立以及多个产品的中国上市、进口与本地化转产项目，并参与肿瘤、代谢、自身免疫等治疗领域的中美及亚太区域I~III期临床试验供应。Shelly于2023年加入礼来中国，现任临床及QC供应链负责人，持续推动中国同步研发策略，强化本地与全球供应流程衔接、注册用药保障及团队能力建设，并积极参与临床供应相关的外部生态系统建设
Shelly graduated from Shenyang University of Chemical Technology with a major in Polymer Chemistry. She has over 15 years of experiences in commercial and clinical supply chain management in multinational pharmaceutical companies (MNCs) including Covance, Sanofi and Amgen, during which she supported the establishment of Asia-Pacific R&D centers, as well as multiple projects involving the launch, import and localization switching of products in China. At the meanwhile, she has also participated in the supply for Phase I-III clinical trials in China, the United States and the Asia-Pacific region in therapeutic areas such as oncology, metabolism and autoimmune diseases.
秦祯（Claire Chin）女士是生命科技投资与人工智能交叉领域的战略领袖，拥有逾15年横跨临床医疗、战略咨询、风险投资及AI产业的跨领域经验。现任INTELLIGEN AI首席产业顾问兼首席战略官，主导生物大语言模型生态建设。她拥有西北大学凯洛格商学院MBA及上海交通大学临床医学本硕学位，兼具顶尖医疗专业与商业战略双重背景。曾任阿里健康董事总经理兼创新药投资负责人，主导了超7000万美元的投资，并推动被投企业达成亚洲最大AI药物授权交易（单项目13亿美元）。目前致力于构建30余家机构的AI协同创新网络，加速药物研发与精准医疗突破。
Ms. Claire Chin is a strategic leader at the intersection of life sciences investment and AI with over 15 years of cross-sector expertise spanning clinical medicine, strategic consulting, venture capital, and artificial intelligence. As Chief Industrial Advisor and Chief Strategy Officer at INTELLIGEN AI, she spearheads biomedical LLM ecosystem development. Holding an MBA from Kellogg School of Management and a clinical medicine dual degree from Shanghai Jiao Tong University, she uniquely bridges deep healthcare and business domains. As former Managing Director at Alibaba Health, head of investment in biopharma, her track record includes leading a $70M+ life science portfolio and securing Asia’s largest AI drug licensing deal ($1.3B per asset). She now pioneers collaborative AI innovation across 30+ institutions to transform drug discovery and precision medicine.
James Liu , Licensed Attorney，holding LL.M.s both from the University of Manchester and one of the top China’s university, as well as a Ph.D. in Management, with twenty years of dedicated experience in the biopharmaceutical and high-tech investment sectors. As a founding practitioner (Founder), I lead the formulation of corporate-wide strategy and development roadmaps, concentrating on core drivers for business growth: effectively integrating critical resources (particularly governmental relations and public policy resources), establishing deep public-private collaborative ecosystems, accurately discerning industry policy trends and driving their translation into execution to ensure corporate compliance and sustained competitive advancement. Leveraging comprehensive expertise spanning R&D, manufacturing, operations management, to investment and financing, I am committed to accelerating the industrialization of innovative achievements and steering organizations toward high-quality, sustainable growth.
刘 James，执业律师，拥有国内外著名高校生物化学本科、双法学硕士及管理学博士学位，于生物医药与高科技投资领域持续深耕二十年。 作为创业实践者（Founder），主导制定企业整体战略与发展路径，聚焦驱动业务增长的核心要素：高效整合关键资源（尤其是政府关系与公共政策资源）、构建深度政企协同生态、精准研判产业政策趋势并推动落地转化，确保企业合规经营与竞争力持续提升。 凭借覆盖研发、生产、管理至投融资的综合经验，致力于促进创新成果产业化，引领企业实现高质量的可持续增长。
With over 30 years of clinical research experience, Gonzalo brings medical, scientific, and business insights to oncology drug development. His understanding of the clinical development – ranging from feasibility assessments, medical monitoring oversight, regulatory strategy, and patient safety enables him to provide valuable guidance to our biopharma partners.
Gonzalo is a board-certified Medical Oncologist with 15+ years of practice in the clinic and as an investigator before leading Global Oncology Medical Teams at the most renowned CROs.
Dominic Jackson is a forward-thinking clinical data professional with deep experience across Central Lab, CRO, and Sponsor environments. He brings a unique, end-to-end perspective on how data can be used more intelligently and creatively in clinical research.
Dominic is particularly interested in how emerging technologies, cross-functional collaboration, and smarter data strategies can unlock new efficiencies and insights. He’s a strong advocate for rethinking traditional approaches and embracing innovation to improve outcomes for both sponsors and patients.
